Skip to main content
Open Access Publications from the University of California

Cyclosporin a corrects daunorubicin resistance in ehrlich ascites carcinoma

  • Author(s): Slater, LM
  • Sweet, P
  • Stupecky, M
  • Wetzel, MW
  • Gupta, S
  • et al.

We have previously developed a daunorubicin resistant subline of Ehrlich ascites carcinoma (EA/DR) for studies on the reversal of daunorubicin resistance. The mean survival of untreated BALB/c mice bearing drug sensitive parental tumour (EA/DS) is 18.4±0.6 days, mice bearing EA/DS treated with five daily doses of 0.3mgkg-1daunorubicin greater than 60 days, and mice bearing EA/DR treated with the same daunorubicin regimen, 21.1 ± 1.4 days. We now report complete reversal of daunorubicin resistance in EA/DR by cyclosporin A (CsA). The in vitro daunorubicin IC50, defined as that concentration of daunorubicin required to inhibit 50% of DNA synthesis, in EA/DR was 6.7±1.15 μgml-1compared to 2.8±0.72 μgml-1in EA/DS. This value was reduced to 2.8±0.52 and 2.1 ± 10.μgml-1daunorubicin by 3.3 and 13.2 μgml-1CsA respectively, P<0.05. The MST of groups of host mice bearing EA/DR either untreated, treated with five daily doses of 0.3mgkg-1daunorubicin, treated with 80mgkg-1CsA in five divided daily doses or treated with combined daunorubicin-CsA were 19.0±1.0, 21.1±1.4, 24.0±2.6 and >60 days respectively. The mean survival of groups of host mice bearing EA/DR treated with 5mgkg-1or 10mgkg-1CsA simultaneously with daunorubicin for five days was also greater than 60 days. These differences are highly significant. © The Macmillan Press Ltd., 1986.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View